{
  "report_rows": [
    {
      "kpi": "Q2 2026 Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$4.44B vs. cons ~$4.43B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Non-GAAP Diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.98 vs. cons ~$2.90",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Health segment operating margin",
      "prediction": "MISS",
      "answer": "pred ~20.5% vs. cons ~22.5%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Revenue guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$18.2B vs. cons ~$18.15B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Non-GAAP EPS guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$12.30 vs. cons ~$12.28 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Health segment forward outlook / DHA-MHS GENESIS revenue impact commentary",
      "prediction": "LOWER",
      "answer": "guide ~-$150M incremental Health revenue headwind vs. cons ~$0 baked in (FY2026-FY2027)",
      "confidence": "LOW"
    },
    {
      "kpi": "Book-to-bill ratio",
      "prediction": "UNCHANGED",
      "answer": "guide ~1.0x for Q2 vs. cons/TTM ~1.1x (Q2 2026 / TTM)",
      "confidence": "LOW"
    },
    {
      "kpi": "Second-half reacceleration narrative (Q3/Q4 revenue & margin step-up)",
      "prediction": "UNCHANGED",
      "answer": "guide reaffirmed H2 acceleration vs. cons already assuming H2 ramp (FY2026 H2)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -2.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -4.0,
  "day5_path": "FADE",
  "day5_rationale": "Headline Q2 revenue/EPS likely land in-line-to-slightly-better since management pre-announced softness and consensus already de-risked, so any initial pop from a clean beat/reaffirm is likely modest. But the Health segment \u2014 hit directly by the DHA/MHS GENESIS integrator transition (Philips/Amwell exiting end of July, Oracle Health by November) \u2014 is where the real out-period math lives: even a reaffirmed FY26 headline (propped up by Entrust) likely comes with incremental, quantified FY26/FY27 Health revenue and margin headwinds that sell-side hadn't fully modeled. As analysts update models over the following days, implicit cuts to FY27 Health margin/EPS get layered in even if Q2 itself 'beats,' producing a fade as the market re-prices the structural margin risk in the higher-margin Health book rather than the transitory Q2 dip that had already been guided.",
  "day5_confidence": "MEDIUM"
}